Effects of Pharmacokinetics-related Genetic Polymorphisms on the Side Effect Profile of Afatinib in Patients with Non-Small Cell Lung Cancer

Lung cancer (LC) is the most common cancer worldwide with an estimated 2+ million newly diagnosed cases annually [1]. Despite the decreasing incidence of mortality, LC accounts for more than 1.2 million deaths annually, with an age-standardized 5-year net survival rate of only 10 to 20% [2]. There are two main types of LC: small cell lung cancer (SCLC) and non-SCLC (NSCLC). NSCLC accounts for approximately 85% of all LC cases [3]. Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are administered as the first-line treatment for patients with advanced EGFR mutation-positive NSCLC.

Source: Lung Cancer - May 16, 2019 Category: Cancer & Oncology Authors: Hideki Hayashi, Hirotoshi Iihara, Chiemi Hirose, Yoshihisa Fukuda, Mika Kitahora, Daizo Kaito, Komei Yanase, Junki Endo, Yasushi Ohno, Akio Suzuki, Tadashi Sugiyama Source Type: research